The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.
Status:
Recruiting
Trial end date:
2025-07-20
Target enrollment:
Participant gender:
Summary
This study was a single-arm, open-label, phase II study of breast cancer patients with brain
metastases. Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle),
etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to
6 cycles were administered, and if patients had a response or stable disease, bevacizumab was
used as maintenance therapy until disease progression or intolerable toxicity.
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital